1 2 2	Airway antibodies wane rapidly after COVID-19 but B cell memory is generated across disease severity
	Alberto Cagigi ¹ Meng Vu ¹ Sara Falck-Jones ¹ Sindhu Vangeti ¹ Biörn Öcterberg ¹ Eric
 5	Åhlberg ¹ Lida Azizmohammadi ¹ Ryan Falck-Jones ^{2,3} Pia C Gubisch ¹ Mert Ödemis ¹
6	Farangies Ghafoor ¹ , Klara Lenart ¹ , Max Bell ^{2,3} , Niclas Johansson ^{4,5} , Jan Albert ^{6,7} , Jörgen
7	Sälde ⁸ . Deleah Pettie ^{9,10} . Michael Murphy ^{9,10} . Lauren Carter ^{9,10} . Neil P King ^{9,10} . Sebastian Ols ¹ .
8	Anna Färnert ^{4,5} , Karin Loré ^{1*} and Anna Smed-Sörensen ^{1*}
9	
10	¹ Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet,
11	Karolinska University Hospital, Stockholm, Sweden. ² Department of Physiology and
12	Pharmacology, Karolinska Institutet, Stockholm, Sweden. ³ Department of Perioperative
13	Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden. ⁴ Division of
14	Infectious Diseases, Department of Medicine Solna, Center for Molecular Medicine,
15	Karolinska Institutet, Sweden. ⁵ Department of Infectious Diseases, Karolinska University
16	Hospital Solna, Stockholm, Sweden. ^o Department of Microbiology, Tumor and Cell Biology,
17	Karolinska Institutet, Stockholm, Sweden. 'Clinical Microbiology, Karolinska University
18	Hospital Solna, Stockholm, Sweden. "Narakut SLSO, Karolinska University Hospital Solna,
20 19	Stockholm, Sweden. ³ Department of Biochemistry, University of Washington, Seattle, WA
20 21	98195, United States. Institute for Protein Design, University of Washington, Seattle, WA
21 22	Solds, Onited States.
22	Karin Lore' and Anna Smed-Sörensen contributed equally to this study.
24	
25	*Corresponding authors:
26	Karin Loré and Anna Smed-Sörensen, Division of Immunology and Allergy, Department of
27	Medicine Solna, Karolinska Institutet, Visionsgatan 4, BioClinicum J7:30, Karolinska
28	University Hospital, 171 64 Stockholm, Sweden.
29	e-mail addresses: <u>karin.lore@ki.se; anna.smed.sorensen@ki.se</u>
30	
31	
32	Introductory paragraph:
33 24	Understanding immune responses following SARS CoV/2 infection in relation to COV/D 10
24 25	soverity is critical to predicting the effects of long term immunological memory on viral
35	spread. Here we longitudinally assessed systemic and airway immune responses against
30	SARS-CoV-2 in a well-characterized cohort of 147 infected individuals representing the full
38	spectrum of COVID-19 severity: from asymptomatic infection to fatal disease. High systemic
39	and airway antibody responses were elicited in patients with moderate to severe disease,
40	and while systemic IgG levels were maintained after acute disease, airway IgG and IgA
41	declined significantly. In contrast, individuals with mild symptoms showed significantly lower
42	antibody responses but their levels of antigen-specific memory B cells were comparable with
43	those observed in patients with moderate to severe disease. This suggests that antibodies in
44	the airways may not be maintained at levels that prevent local virus entry upon re-exposure
45	and therefore protection via activation of the memory B cell pool is critical.
46	
47	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

All rights reserved. No reuse allowed without permission.

48 Main:

49

50 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes 51 coronavirus disease 2019 (COVID-19) can present with a wide range of disease severity from 52 asymptomatic to fatal. Individuals of advanced age and/or those with comorbidities are 53 overrepresented among those who develop severe disease¹. However, the majority of SARS-54 CoV-2 infected individuals experience asymptomatic infection or only mild disease². 55 Whether patients with different disease severities generate similar protective immunity is 56 still unknown. Here we present data generated from a clinically well-characterized cohort of 57 individuals with SARS-CoV-2 infection (n=147) representing the full spectrum of COVID-19 58 severity ranging from asymptomatic infection to fatal disease. Individuals were sampled 59 during acute disease and convalescence with longitudinal, matched blood and airway 60 samples. The levels of systemic and airway antibody responses as well as the generation of 61 SARS-CoV-2-specific memory B cells were measured. Plasma, peripheral blood mononuclear 62 cells (PBMC), nostril swabs (NSW) and nasopharyngeal aspirates (NPA) were collected across 63 all disease severities whereas endotracheal aspirates (ETA) were collected only from 64 intubated patients receiving intensive care (Figure 1a). Disease severity was assessed on a 65 seven-point scale derived from the respiratory domain of the sequential organ failure assessment (SOFA) score^{3,4}, with additional levels for non-admitted mild cases (1) and fatal 66 67 cases (7). Patients were grouped based on peak disease severity (PDS) (Supplementary table 68 1 and online methods). In addition, pre-pandemic healthy controls (PPHC) (n=30) as well as 69 individuals who experienced influenza-like symptoms and were possibly exposed to SARS-

70 Cov-2 but had a negative diagnostic PCR (PCR-) (n=9) were sampled in the same way and

71 included as controls (Supplementary table 2 and online methods).

72

73 We first assessed systemic IgG and IgA responses at the time of study inclusion that ranged 74 between 0-54 days from onset of symptoms; median 16 days, and at the first follow-up visit 75 during convalescence (46-168 days; median 108 days). Plasma IgG and IgA against the SARS-76 CoV-2 nucleocapsid (N) and spike (S) proteins as well as the receptor binding domain (RBD)^{5,6} 77 of the S protein were measured by ELISA. Antibody responses against the internal N protein have been shown to be elevated in deceased individuals but whether these antibodies 78 contribute to disease severity is unknown^{7,8}. In contrast, responses against the viral surface 79 80 protein S and, in particular, against the RBD result in virus neutralization⁹. Responses against 81 the RBD are thus likely necessary for protection from re-infection or prevention of 82 symptomatic disease.

83

In line with previous reports^{7,8,10-12}, IgG and IgA responses against N, S and RBD were robust 84 85 in acute disease in the majority of individuals with moderate to severe disease while they 86 were substantially lower in individuals with mild disease (Figure 1b). However, in our cohort, 87 this might also partially be due to earlier study inclusion of patients with mild symptoms 88 (median days from onset of symptoms 11 as compared with 13 and 21.5 in the moderate 89 and severe groups respectively, and 13 in the fatal group) (Supplementary table 1). In fact, 90 while IgG levels remained high in the patients with moderate to severe disease in the 91 convalescent phase, levels had increased in the individuals with mild disease. In contrast, IgA 92 levels from the acute phase, against all antigens, waned substantially during convalescence 93 in most patients (Figure 1b and supplementary fig. 1a). While the levels of IgG against the 94 RBD (Figure 1c), as well as against N and S (Supplementary fig. 1b), exhibited a positive

All rights reserved. No reuse allowed without permission.

95 correlation with days from onset of symptoms during the acute phase, this was less

96 pronounced for IgA levels. Altogether, these data confirm that the generation of IgA likely

97 precede that of IgG. Earlier reports of individuals with asymptomatic infection or mild

98 disease also showed robust early IgA responses¹³⁻¹⁵.

99

100 Comparably to another study¹⁶, the levels of both IgG and IgA against all antigens tested,

101 during both acute disease and convalescence, correlated directly with disease severity

102 (Supplementary fig. 2a), indicating that individuals with severe disease or even fatal

103 outcome mounted the highest antibody responses against SARS-CoV-2 antigens. In our

104 cohort, this is further supported by the fact that the patients with moderate/severe disease105 and fatal outcome for whom we initially observed low IgG titers against RBD, had an early

106 study inclusion (on average 13 days from onset of symptoms); but showed significantly

107 higher titers later during the acute phase (on average 19 days) (Figure 1d-e). Similar kinetics

108 of anti-RBD responses have previously been noted in different patient cohorts¹⁷⁻¹⁹.

109

110 In line with previous reports, the Charlson Comorbidity Index (CCI) and the Body Mass Index

111 (BMI) were associated with disease severity¹ in the cohort (Supplementary fig. 3). However,

112 the presence of comorbidities did not impact the ability to generate antibodies against any

113 of the antigens analyzed (Supplementary fig. 2b).

114

115 As the respiratory tract is the initial site of viral infection and replication, we next measured 116 the levels of IgG and IgA in the upper and lower airways and compared with levels in plasma 117 at matched time points. Due to limited sample volumes, we focused our analyses on IgG and 118 IgA responses against the RBD since these responses are likely most critical for virus 119 neutralization. We found that RBD-specific antibodies could be readily detected in NSW and 120 NPA during the acute phase in several patients across all disease severities (Figure 2a-b and 121 supplementary fig. 4a). In agreement with our observations in plasma, antibody levels in the upper respiratory tract were higher in patients with moderate or severe disease as 122 123 compared with individuals with mild disease (Figure 2a-b). Both IgG and IgA levels declined 124 significantly in the convalescent phase, with IgG declining to almost undetectable levels (Figure 2a-b). This demonstrates that airway antibody levels wane much faster than those in 125 126 plasma during convalescence. Low but detectable levels of antibodies to SARS-CoV-2 have previously been reported also in saliva during convalescence²⁰. However, whether these low 127 128 antibody levels at mucosal sites will be sufficient for protection is not known. We found that 129 RBD-specific IgG and IgA levels in the respiratory tract correlated well with those in plasma 130 during the acute phase but to a lesser extent during convalescence (Supplementary fig. 4b 131 and supplementary fig. 5). When comparing matched NSW, NPA and ETA collected at the 132 same time point during acute disease from intubated patients, significantly higher levels of 133 IgA against the RBD were found in NPA as compared with NSW and ETA (Figure 2c). While 134 this could be partially influenced by differences in sampling method and sample volume, 135 these data suggest that antibody abundance and possibly virus neutralization via IgA differs 136 along the respiratory tract and may be more pronounced in the nasopharynx compared to 137 the lower airways. Hence, nasopharynx antibodies (both IgG and IgA) showed a strong 138 correlation with plasma antibody responses (Supplementary fig. 4b and supplementary fig. 139 5). We also assessed the presence of B cells in the respiratory tract of COVID-19 patients by 140 analyzing the lymphocytes that could be retrieved from NPA and ETA as compared with NPA 141 from three healthy controls (HC). Lymphocyte frequencies were lower in both NPA and ETA

All rights reserved. No reuse allowed without permission.

from several COVID-19 patients as compared with NPA from HC. However, the relative
proportion of B cells was not different. In addition, we observed that in the COVID-19

proportion of B cells was not different. In addition, we observed that in the COVID-19 patients, the frequencies of B cells were higher in NPA as compared with ETA which possibly

145 contributes to the higher antibody levels at this site (Supplementary fig. 6).

146

147 Altogether, the data presented so far confirm that moderate and severe COVID-19 result in 148 high levels of circulating antibodies and show that despite IgG being well-maintained during 149 convalescence, antibody levels in the airways decline significantly after the acute phase. 150 Generally, antibodies present in circulation and at local sites are the result of secretion from short-lived plasmablasts and/or terminally differentiated plasma cells in the bone marrow or 151 152 mucosal sites²¹. The response to a secondary infection once antibody titers have waned 153 below protective levels mostly relies on the presence of resting antigen-specific memory B cells that are rapidly activated upon antigen re-exposure²¹. We therefore investigated the 154 induction and maintenance of antigen-specific memory B cells similar to other studies²²⁻²⁴. 155 156 We focused on the direct comparison between individuals with mild disease and patients 157 with moderate/severe disease, along with individuals who had reported mild influenza-like 158 symptoms but were SARS-CoV-2 PCR-. Patients with moderate/severe disease who had high 159 circulating IgG and IgA levels were specifically selected for the analysis to be able to compare the opposite ends of the COVID-19 disease spectrum. Matched PBMC from acute disease 160 161 and convalescence were analyzed side-by-side using fluorescently labelled S and RBD probes to detect antigen-specific B cells²²⁻²⁴. Patients with moderate/severe disease had switched 162 163 memory B cells specific to S in the acute phase and the memory B cell pool had further 164 expanded in the convalescent phase (ranging from 0.009 to 1.35%; mean 0.42% during 165 convalescence) (Figure 2d-e). Individuals with mild disease showed lower memory B cells during acute disease than the patients with moderate/severe disease, but the levels had 166 167 increased by the time of convalescent sampling (ranging from 0.17% to 0.64%; mean 0.35% 168 during convalescence) and were comparable between the groups (Figure 2d-e and supplementary fig. 6). Further phenotyping of the S-specific memory B cells indicated that 169 170 the majority of these cells may be specific for epitopes on S outside of the RBD (Figure 2f). 171 However, it is possible that binding of B cells to RBD could be underestimated as RBD is also 172 present in the S protein. S-specific memory B cells in the circulation were predominantly 173 IgG+, rather than IgA+ (Figure 2f). Low frequencies of S and RBD-specific memory B cells 174 were observed in the PCR- individuals (Figure 2e). However, these were not significantly 175 different from the levels observed in PPHC (Supplementary fig. 7). Collectively, since the 176 majority of individuals infected with SARS-CoV-2 are either asymptomatic or experience only mild COVID-19 symptoms², the possibility of generating antigen-specific memory B cells 177 178 without experiencing severe disease, would be very important in the prospect of 179 establishing potential immunity at the population level. 180 181 In summary, here we show that COVID-19 disease severity not only determines the 182 magnitude of systemic but also airway antibody levels with efficient generation of virus-183 specific memory B cells against SARS-CoV-2 also occurring upon mild disease. While plasma 184 IgG levels were generally well detectable at convalescence in all groups, there was a

185 significant decline in airway antibodies after the clearance of infection. This suggests that

- 186 antibodies in the airways may not be maintained at levels that prevent local virus entry upon
- 187 re-exposure. However, our data indicate that the majority of infected individuals have the
- ability to generate anamnestic responses via the memory B cell pool and thereby may be

All rights reserved. No reuse allowed without permission.

- 189 protected or mitigate disease severity. Whether sufficient number of memory B cells will be
- 190 maintained long-term and to what extent they will prevent the spread of SARS-CoV-2 at the
- 191 population level remain to be understood. This is critical knowledge to acquire in the near
- 192 future to evaluate together with the memory B cell response generated after the
- 193 introduction of SARS-CoV-2 vaccination. Ultimately, the requirements for establishment of
- 194 long-term protection and immunity will need to be determined.
- 195
- 196

197 Methods

198

199 Study design, patient enrollment and sample collection

200 One hundred and forty-seven (147) PCR-confirmed SARS-CoV-2 infected patients were

201 enrolled at the Karolinska University Hospital and Haga Outpatient Clinic (Haga Närakut),

Stockholm, Sweden during March-May 2020 (acute phase) and during April-September 2020
 (convalescence). Patients were enrolled at various settings, ranging from primary to

203 (convalescence). Facients were enrolled at various settings, ranging non prinary to

- intensive care. In order to recruit asymptomatic and mild cases, household contacts of
- 205 COVID-19 patients were screened with PCR and enrolled if positive. A small subset of these
- individuals who experienced influenza-like symptoms and were possibly exposed to SARS-
- 207 Cov-2 but had a negative diagnostic PCR (PCR-) (n=9 of whom 3 were household contacts of 208 confirmed patients, 4 had symptoms including fever and 2 had symptoms but no fever) were
- sampled in the same way and included as controls alongside with 30 pre-pandemic healthy
- 210 control samples (PPHC) from 2016-2018.
- 211

212 Respiratory failure was categorized daily according to the respiratory domain of the

- 213 Sequential Organ Failure Assessment score (SOFA)³. The modified SOFA score (mSOFA) was
- calculated when arterial partial pressure of oxygen (PaO₂) was not available. In this case
- 215 peripheral transcutaneous hemoglobin saturation (SpO₂) was used instead⁴. Estimation of
- the fraction of inspired oxygen (FiO₂) based on O₂ flow was calculated as per the Swedish
- 217 Intensive Care register definition²⁵. Patients were categorized based on the peak respiratory
- 218 SOFA or mSOFA value with the 5-point respiratory SOFA score being extended with
- additional levels to include and distinguish admitted asymptomatic and non-
- admitted/admitted mild cases and to include fatal outcome added as a seventh level. Ten
- 221 (10) patients with fatal outcome had peak disease severity score 6 prior to death and 2
- patients had scores of 4 and 5. For convenience, the resulting 7-point composite peak
- disease severity (PDS) was condensed into a broader classification consisting of mild (1-2),
- 224 moderate (3-4), severe (5-6), and fatal (7). Demographics and additional data were collected
- from medical records, including clinical history and risk factors such as BMI and co-
- 226 morbidities. Total burden of comorbidities was assessed using the Charlson co-morbidity
- index (CCI)²⁶ (Supplementary table 1). Additional clinical information on this patient cohort
- 228 can also be found in Falck-Jones et al²⁷.
- 229

230 Blood was collected in EDTA-containing tubes from all patients except those admitted to the

- 231 intensive care unit (ICU) for whom blood was pooled from heparin-coated blood gas syringes
- discarded in the last 12 hours. For some ICU patients, additional venous blood was also
- collected in EDTA tubes. Nostril swabs (NSW) and nasopharyngeal aspirates (NPA) were
- collected from the majority of the patients whereas endotracheal aspirates (ETA) were only
- collected from patients with mechanical ventilation intubated in the ICU. Admitted patients

All rights reserved. No reuse allowed without permission.

- 236 were sampled during acute disease at up to four timepoints and ICU patient material was
- 237 collected up at to ten timepoints. For this study, unless otherwise stated, the measurements
- 238 referring to acute disease were performed with samples collected at the time of study
- 239 inclusion and during convalescence when patients returned for a follow-up visit.
- 240
- 241 The study was approved by the Swedish Ethical Review Authority, and performed according 242 to the Declaration of Helsinki. Written informed consent was obtained from all patients and
- 243 controls. For sedated patients, the denoted primary contact was contacted and asked about
- 244 the presumed will of the patient and to give initial oral and subsequently signed written
- 245 consent. When applicable retrospective written consent was obtained from patients with
- 246 non-fatal outcomes.
- 247

248 Enzyme-linked immunosorbent assay (ELISA)

249 The presence of IgG or IgA binding against the SARS-Cov-2 Nucleocapsid (N) and Spike (S) 250 trimer or the Receptor Binding Domain (RBD) monomer⁵ in plasma and airway samples was 251 assessed by enzyme-linked immunosorbent assay (ELISA). Recombinant proteins were 252 received through the global health-vaccine accelerator platforms (GH-VAP) funded by the 253 Bill & Melinda Gates Foundation. Briefly, 96-half well plates were coated with 50ng/well of the respective protein. Plates were incubated with a selected duplicate dilution that did not 254 255 provide background noise against ovalbumin used as a negative control (data not shown) 256 (i.e. 1:20 for plasma samples, 1:2 for NSW and NPA, and 1:5 for ETA in 5% milk/PBS buffer). 257 Duplicate 7-point serial dilutions were initially performed for measuring plasma IgG against 258 RBD during acute disease and the half maximal effective concentration (EC_{50}) was calculated 259 using GraphPad Prism 9. However, since for several samples with low antibody

- 260 concentration (mostly from the asymptomatic/mild category) the EC₅₀ was below the highest
- 261 dilution used (of 1:20) and therefore below the limit of detection (Supplementary fig. 8a), 262
- the maximal optical density (OD) at 1:20 dilution was used instead for this and for all the other measurements subsequently performed. The relation with maximal OD and EC₅₀ was 263
- 264 also verified in a subset of patients with high IgG and IgA against S (Supplementary fig. 8b).
- 265 Detection was performed with mouse and goat anti-human IgG or IgA HRP-conjugated
- 266 secondary antibodies (clone G18-145 from BD Biosciences and polyclonal from
- 267 ThermoFisher, respectively) followed by incubation with TMB substrate (BioLegend) which 268 was stopped with a 1M solution of sulfuric acid. Blocking with 5% milk/PBS buffer and
- 269 washing with 0.1% Tween-20/PBS buffer were performed between each step. Absorbance
- 270 was read at 450nm and background correction at 550nm using an ELISA reader. Data were
- 271 reported as maximal absorbance i.e. OD, as stated above, and plotted using GraphPad Prism
- 272 9. All of the antibody measurements in plasma and respiratory samples from SARS-CoV-2
- 273 patients were run alongside with samples from two different control groups as described
- 274 above. Interestingly, low but readily detectable IgA reactivity against S was detected in the
- 275 pre-pandemic healthy controls and in the PCR- individuals (Supplementary fig. 8b). After
- 276 having verified the specificity and sensitivity of our ELISA assay for IgA detection with
- 277 limiting sample dilutions (Supplementary fig. 8c), we hypothesize that this might be due to
- 278 cross-reactivity on the shared portions of the S protein between SARS-CoV-2 and other
- 279 common cold coronaviruses. Reports have shown that cross-reactivity between coronaviruses exists^{28,29}.
- 280 281
- 282

All rights reserved. No reuse allowed without permission.

283 Flow cytometry

Staining of cells from airway samples was performed fresh. Briefly, samples were centrifuged 284 285 at 400 g for 5 min at room temperature and cells were washed with sterile PBS. Mucus was 286 removed using a 70 μ m cell strainer and cells were subsequently stained with the 287 appropriate combination of fluorescently labelled monoclonal antibodies as illustrated in 288 Supplementary table 3a. Staining of PBMC was performed on previously cryopreserved 289 samples. The appropriate combination of fluorescently labelled monoclonal antibodies 290 binding to different cell surface markers and with fluorescently labelled S and RBD proteins 291 used as probes for antigen-specific B cells is illustrated in Supplementary table 3b. Probes 292 were prepared from biotinylated proteins using a 4:1 molar ratio (protein:fluorochrome-293 labelled streptavidin) considering the molecular weight of protein monomers and of the 294 streptavidin only. The probes were prepared using streptavidin conjugated to PE and APC for 295 S and with BV421 for the RBD. The gating strategy for the identification of antigen-specific 296 memory B cells is shown in Figure 2d. Briefly, after identification of lymphocytes in single 297 suspension, live B cells, (i.e. cells not expressing CD3/,CD14/CD16/CD56) were gated. From 298 this gate, B cells were further isolated by expression of CD19 and CD20 and then switched 299 memory B cells were identified as IgD-IgM-. From these, S-specific switched memory B cells 300 were identified by binding to both S protein probes. Further characterization was then 301 carried out by analyzing IgG expression (IgA+ switched memory B cells are assumed to mirror 302 IgD-IgM-IgG- B cells) and fluorescently labelled RBD. Stained cells from airway samples were 303 acquired using a BD LSRFortessa while stained PBMC were acquired using a BD FACSAria 304 Fusion both interfaced with the BD FACSDiva Software. Results were analyzed using BD 305 FlowJo version 10.

306

307 Statistical analyses

308 All statistical analyses were performed using GraphPad Prism 9. Spearman correlation was

- 309 used to assess the interdependence of 2 different non-categorical parameters across
- 310 individuals whereas Wilcoxon matched-pairs signed rank or Mann–Whitney U tests as
- 311 appropriate, were used to assess differences or similarities for one single parameter
- between 2 different groups. Kruskal -Wallis with Dunn's multiple comparisons test was used
- 313 when assessing comparison between multiple groups.
- 314
- 315

316 Acknowledgments

We thank the patients and healthy volunteers who have contributed to this study. We would also like to thank medical students and hospital staff for assistance with patient sampling and collection of clinical data, the Biomedicum BSL3 core facility, Karolinska Institutet and Fredrika Hellgren for assistance with English editing. This work was supported by grants from the Swedish Research Council, the Swedish Heart-Lung Foundation, the Bill & Melinda Gates Foundation, the Knut and Alice Wallenberg Foundation through SciLifeLab and Karolinska Institutet.

- 324
- 325
- 326

_

327 Author contributions 328 Experimental study design: A.C., Ka.L. and A.S-S. Clinical concept design: A.S-S., M.B., N.J., 329 J.A., J.S. and A.F. Acquisition and sample processing: M.Y., S. F-J., S.V., B.Ö., E.Å., L.A., R.F-J., 330 M.Ö. and F.G. Generation of data: A.C., M.Y., S. F-J., S.V. and P.C.G. Provision of custom 331 reagents: D.P., M.M., L.C., and N.P.K. Analysis and interpretation of data: A.C., Ka.L. and A.S-332 S. Critical revision of the manuscript: all authors. Statistical analysis: A.C., K.L. and S.O. Ka.L. 333 and A.S-S. contributed equally to the study. 334 335 336 **Competing interests** The authors declare no competing financial interests. 337 338 339 340 References 341 342 Zaki, N., Alashwal, H. & Ibrahim, S. Association of hypertension, diabetes, stroke, 1. 343 cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and 344 fatality: A systematic review. Diabetes Metab Syndr 14, 1133-1142 (2020). 345 Moghadas, S.M., et al. The implications of silent transmission for the control of 2. 346 COVID-19 outbreaks. Proc Natl Acad Sci U S A (2020). 347 3. Vincent, J.L., et al. The SOFA (Sepsis-related Organ Failure Assessment) score to 348 describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-349 Related Problems of the European Society of Intensive Care Medicine. Intensive Care 350 Med 22, 707-710 (1996). 351 Grissom, C.K., et al. A modified sequential organ failure assessment score for critical 4. 352 care triage. Disaster Med Public Health Prep 4, 277-284 (2010). 353 Walls, A.C., et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike 5. 354 Glycoprotein. Cell 181, 281-292 e286 (2020). 355 Wrapp, D., et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion 6. 356 conformation. Science 367, 1260-1263 (2020). Atyeo, C., et al. Distinct Early Serological Signatures Track with SARS-CoV-2 Survival. 357 7. 358 Immunity 53, 524-532 e524 (2020). 359 8. Guthmiller, J.J., et al. SARS-CoV-2 infection severity is linked to superior humoral 360 immunity against the spike. *bioRxiv* (2020). 361 9. Piccoli, L., et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 362 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell 363 (2020). 364 Zhao, J., et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus 10. 365 Disease 2019. Clin Infect Dis 71, 2027-2034 (2020). 366 Gudbjartsson, D.F., et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N 11. 367 Engl J Med 383, 1724-1734 (2020). Gaebler, C., et al. Evolution of Antibody Immunity to SARS-CoV-2. bioRxiv (2020). 368 12. 369 13. Cervia, C., et al. Systemic and mucosal antibody secretion specific to SARS-CoV-2 370 during mild versus severe COVID-19. bioRxiv, 2020.2005.2021.108308 (2020). 371 14. Staines, H.M., et al. Dynamics of IgG seroconversion and pathophysiology of COVID-372 19 infections. medRxiv (2020).

373 374	15.	Sterlin, D., et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. medRxiv (2020).
375 376	16.	Hansen, C.B., <i>et al.</i> SARS-CoV-2 Antibody Responses Are Correlated to Disease Severity in COVID-19 Convalescent Individuals. <i>J Immunol</i> (2020).
377 378	17.	Rydyznski Moderbacher, C., <i>et al.</i> Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. <i>Cell</i> (2020).
379 380	18.	Lynch, K.L., <i>et al.</i> Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. <i>Clin Infect Dis</i> (2020).
381 382	19.	Robbiani, D.F., <i>et al.</i> Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> (2020).
383 384	20.	Isho, B., <i>et al.</i> Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. <i>Sci Immunol</i> 5 (2020).
385 386	21.	Zielinski, C.E., <i>et al.</i> Dissecting the human immunologic memory for pathogens. <i>Immunol Rev</i> 240 , 40-51 (2011).
387 388	22.	Dan, J.M., <i>et al.</i> Immunological memory to SARS-CoV-2 assessed for greater than six months after infection. <i>bioRxiv</i> , 2020.2011.2015.383323 (2020).
389 390	23.	Rodda, L.B., <i>et al.</i> Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i> (2020).
391 392	24.	Juno, J.A., <i>et al.</i> Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nat Med</i> (2020).
393	25.	Intensivvårdsregistret, S. SIR:s riktlinje för registrering av SOFA (2018).
394 395 396	26.	Charlson, M.E., Pompei, P., Ales, K.L. & MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. <i>J Chronic Dis</i> 40 , 373-383 (1987).
397 398	27.	Falck-Jones, S., <i>et al.</i> Functional myeloid-derived suppressor cells expand in blood but not airways of COVID-19 patients and predict disease severity. <i>medRxiv</i> (2020).
399 400 401	28.	Grifoni, A., <i>et al.</i> Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. <i>Cell</i> 181 , 1489-1501 e1415 (2020).
402 403 404 405 406	29.	Song, G., <i>et al.</i> Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. <i>bioRxiv</i> (2020).

All rights reserved. No reuse allowed without permission.

407 Figure legends

408

Figure 1. Plasma IgG and IgA responses to N, S and RBD across COVID-19 severity during acute disease and convalescence.

411 a) Overview of study cohort and controls, timeline of longitudinal sampling, the anatomical 412 compartments analyzed, and the measurements performed. AS=asymptomatic. b) Scatter 413 plots show individual levels of plasma IgG and IgA (from left to right) in SARS-CoV-2 infected 414 individuals with different peak disease severity (PDS). Data in cyan and green refer to mild 415 disease (PDS 1 and 2), yellow and orange refer to moderate disease (PDS 3 and 4), red and 416 cayenne refer to severe disease (PDS 5 and 6) and grey refers to patients with fatal outcome 417 (PDS 7). Black lines indicate medians and dotted lines indicate the average background level 418 from PPHC. Mann-Whitney U was used to compare the groups. c) Spearman correlation for 419 plasma immunoglobulins against the RBD versus days from onset of symptoms during the 420 acute and the convalescent phases are shown. Circles with black lining refer to convalescent 421 samples. d-e) Longitudinal measurements of plasma IgG against RBD on a subset of patients 422 with moderate/severe disease and fatal outcome who had low antibody titers at the time of 423 study inclusion. Levels are shown at the time of study inclusion, during the late acute phase 424 and at convalescence, and shown with respect to days from onset of symptoms and as a 425 group comparison. The black lines connect data points from the same individuals. Wilcoxon 426 test was used to compare the groups separately. 427 428 Figure 2. Airway IgG and IgA responses to RBD and circulating S-specific memory B cells 429 across COVID-19 severity during acute disease and convalescence. a) Scatter plots of the

levels of IgG and IgA to RBD in the upper airway. The black lines indicate median values.
Mann-Whitney U was used to compare the groups. b) Heat map generated by sorting data

- Mann-Whitney U was used to compare the groups. b) Heat map generated by sorting data
 according to PDS. The heat map also includes data from PPHC and PCR- as a reference
- 432 (indicated with PDS 0). Missing data and not available/applicable samples are shown in
- 434 black. **c)** Comparison of the levels of RBD IgG/A in different upper and lower airway
- 435 compartments. Data on plasma are shown as a reference. The black lines connect data
- 436 points from the same individuals. Wilcoxon test was used to compare the groups separately.
- **d)** Representative example with gating strategy of SARS-Cov-2-specific memory B cells from
- 438 the four different categories analyzed, and example of further characterization on RBD
- binding and B cell isotype (IgG+ or IgA+ assumed to correspond to IgD-IgM-IgG- B cells). **e**)
- 440 Scatter plot shows the quantification of S-specific memory B cells in matched acute (filled)
- 441 and convalescent (filled with black lining) PBMCs in relation to days in the subset of
- 442 individuals analyzed color-coded according to PDS. **f**) Pie charts showing the cumulative
- characterization of RBD binding and memory B cell isotypes. The dotted lines on a) and e)indicate the average background level from PPHC. In a) the line overlaps with not detected
- 445 (ND) for IgG levels.
- 446
- 447



